♥ HF Guideline NavigatorESC 2026

11 › 11.6 › 11.6.2

11.6.2 Advance care planning and palliative care

Pages 73–74 · open in PDF

Recommendations in this section

  • Class ILevel B1Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to facilitate communication on end of life and QoL.
  • Class ILevel B2Access to an integrated HF palliative care multidisciplinary team is recommended for patients in an advanced HF stage to improve QoL and reduce symptom burden.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 73 · PDF

 Symptomatic heart failure

 Advanced heart failure

           

      

                        

                     

     

     

† ‡       

Figure 22 Long-term follow-up of patients with stable heart failure—what—when—who. CIED, cardiac implantable electronic device; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HF, heart failure; HF-MDT, heart failure multidisciplinary team; RHC, right heart catheterization. aIf deemed clinically relevant. bCheck ‘I NEED HELP’ criteria, Figure 16; Table 15 (Section 8). c Intervals may be shorter.

status, liver, kidney, and thyroid function). What is needed, at which interval and who has to perform the follow-up assessment depend on HF stage (Figure 22). The necessity of cardiologist-led follow-up for these patients remains uncertain, with some studies suggesting that primary care follow-up may be appropriate.1054 However, evidence-based intervention uptake is low in many settings, and studies indicate that follow-up by an HF clinic, alongside quality improvement registries, may lead to better therapy optimization and improved outcomes.990,994,1054–1057 An ECG is recommended to detect QRS prolongation, which may qualify patients for CRT, as well as to identify conduction disturbances, AF, and other arrhythmias. Echocardiography should be performed if there is clinical deterioration or if otherwise deemed relevant. Trials investigating the use of biomarkers, such as BNP and NT-proBNP, to guide therapy in HFrEF have yielded inconsistent results.1058–1060 Although these biomarkers are strong prognostic indicators, it remains unclear what additional value a biomarker-guided strategy offers beyond strict adherence to FMT. As such, routine biomarker measurement for guidance on diuretic therapy is not currently supported by the evidence.

11.6.2. Advance care planning and palliative care While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading to death. Communication about disease trajectory and advance care planning should be incorporated by all healthcare professionals throughout the course of the disease.1061,1062 Advance care planning is a structured process that facilitates the exploration and communication of the patient’s personal values, life goals, and preferences regarding future medical care, and may include preferences for place of death and resuscitation (which may include deactivating devices, such as ICD or durable MCS). Advance care planning should be documented, regularly reviewed, and routinely communicated to all those involved in the patient’s care. Evidence shows that proactive advance care planning can reduce hospitalizations and improve QoL and end-of-life care, yet many patients with HF lack formalized plans, highlighting the need for better implementation.627 Palliative care, defined as patient- and family-centred care aimed at optimizing health-related QoL by anticipating, preventing, and alleviating suffering, should be integrated into the management of patients with HF in an advanced stage of the

 At risk for heart failure

Page 74 · PDF

disease. The role of palliative and supportive care spans the entire course of HF, beginning early in the disease, intensifying as the condition progresses, and extending into caregiver bereavement. Evidence supports the use of multidisciplinary palliative care in people with advanced HF to improve patient-reported outcomes (symptom burden, depression, functional status, QoL), but trials do not identify who would benefit most from specialist palliative referral.1063–1065 There are no sufficiently robust multicentre evaluation phase trials to provide generalizable findings.

In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta1-selective blockers (metoprolol, bisoprolol) with close mother and

teratogenicity.1074–1076 ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a Class of recommendation. b Level of evidence.

QoL and reduce symptom burden.1066–1068 HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence.

12.2.1. Hypertrophic cardiomyopathy Patients with HCM may develop HFrEF; in such cases, they should in general be treated as other patients with HFrEF. However, many patients develop symptoms of HF without having HFrEF, and these should be treated according to the cardiomyopathy guidelines (see Supplementary data online, Section S9.2).124

12. Specific conditions 12.1. Pregnancy and heart failure Heart failure in pregnancy requires careful multidisciplinary management.1069–1071 The core components of HF care in pregnancy involves multiple aspects from pre-conception to postpartum (see Supplementary data online, Table S26). Specific recommendations for pre-conception care and management of HF during pregnancy can be found in Recommendation Table 27. For an overview of managing HF in pregnancy, see Supplementary data online, Section S9.1. For a comprehensive and detailed guidance, we refer to the 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy.7

Recommendation Table 27 — Recommendations for heart failure and pregnancy (see Evidence Tables 103–107) Recommendations

Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive

patients in an advanced HF stage to improve

Cardiomyopathies are a common and specific cause of HF.124 The 2023 ESC Guidelines for the management of cardiomyopathies described cardiomyopathy phenotypes based on structural (e.g. ventricular hypertrophy, dilatation, or scar) and functional (e.g. systolic or diastolic dysfunction) features.124 Detailed recommendations and algorithms for the diagnosis and management of cardiomyopathies are provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124

12.3. Amyloidosis 12.3.1. Epidemiology and diagnosis Cardiac amyloidosis is an infiltrative cardiomyopathy caused by amyloid fibril deposition in the extracellular space, resulting in increased myocardial thickness and stiffness, leading to a restrictive physiology.1077,1078 The two most prevalent forms of CA are immunoglobulin light chain CA (AL-CA) and transthyretin amyloidosis (ATTR). Transthyretin amyloidosis includes the wild-type (>90% of cases), and the hereditary or variant forms.1077 Greater awareness of CA, streamlined diagnostic processes, and the emergence of new treatments has led to an increase in the prevalence of CA.1079,1080 The prevalence of CA is higher in males.1081 Cardiac amyloidosis should be suspected in patients with HF and increased LV wall thickness in the presence of specific red flags (Table 20), particularly in patients aged >65 years. A timely, definitive diagnosis should be obtained as patient outcomes depend largely on early initiation of therapy (particularly in AL-CA). Cardiac amyloidosis can be diagnosed using both invasive and non-invasive diagnostic criteria. Invasive diagnostic criteria apply to all forms of CA, whereas non-invasive criteria are accepted only for transthyretin CA (ATTR-CA).1077 Figure 23 displays the diagnostic work-up and treatment options. For more diagnostic details, the Task Force refers to the 2021 ESC position statement on CA.1077

SGLT2-Is are not recommended during pregnancy due to the risk of foetotocixity or

facilitate communication on end of life and QoL.627 Access to an integrated HF palliative care multidisciplinary team is recommended for

ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and

Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to

foetal events and a lower birth weight.1072,1073

foetus monitoring to reduce the risk of adverse

Recommendation Table 26 — Recommendations for longterm follow-up (see Evidence Tables 101 and 102) Recommendations